Evaluating the Effectiveness of a Self-management Transdiagnostic Cognitive Treatment for Insomnia: The YAC Study.

Conditions:   Insomnia;   Chronic Pain;   Insomnia Due to Medical Condition Intervention:   Behavioral: DOZE app Sponsors:   Women's College Hospital;   Ryerson University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Clin J Am Soc Nephrol. 2022 Jan 5:CJN.11560821. doi: 10.2215/CJN.11560821. Online ahead of print.ABSTRACTPeople with kidney failure can experience a range of symptoms that lead to suffering and poor quality of life. Available therapies are limited, and evidence for new treatment options is sparse, often resulting in incomplete relief of symptoms. There is growing interest in the potential for cannabinoids, including cannabidiol and tetrahydrocannabinol, to treat symptoms across a wide range of chronic diseases. As legal prohibitions are withdrawn or minimized in many jurisdictions, patients are increasingly able to access ...
Source: Clinical Journal of the American Society of Nephrology : CJASN - Category: Urology & Nephrology Authors: Source Type: research
Conclusion: Comprehensive cancer management plan should include psychological counseling, emotional support, physiotherapy care for pain and other musculoskeletal problems etc. along with medical treatment of patients with breast cancer.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the R...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson &Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conditions:   Insomnia;   Chronic Pain;   Insomnia Due to Medical Condition Intervention:   Behavioral: DOZE app Sponsors:   Women's College Hospital;   Ryerson University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The objective of this study was to systematically review the literature on the effects of cognitive behavioral therapy (CBT) on insomnia and pain in patients with traumatic brain injury (TBI). PubMed, Embase, the Cochrane Library, Cumulative Index to Nursing and Allied Health, and Web of Science databases were searched. Outcomes, including pain, sleep quality, and adverse events, were investigated. Differences were expressed using mean differences (MDs) with 95% confidence intervals (CIs). The statistical analysis was performed using STATA 16.0. Twelve trials with 476 TBI patients were included. The included studies did no...
Source: Neural Plasticity - Category: Neurology Authors: Source Type: research
More News: Hospitals | Insomnia | Pain | Pain Management | Research | Study | Women